Bone marrow transplants save lives. But in some patients, the immune system rebuilt to cure cancer becomes the source of life-threatening damage.

That complication is called graft-versus-host disease (GVHD), a serious and sometimes fatal condition that occurs when donor immune cells attack the patient’s own tissues. When GVHD strikes the gut, it can become especially severe, driving inflammation that is closely linked to transplant-related mortality.

For years, scientists have been trying to answer a critical question: Why do some immune cells become dangerously inflammatory after transplant, and can that reaction be controlled without weakening the immune cells’ ability to fight cancer?

MCW researchers in the Drobyski Lab may have uncovered an important piece of that puzzle.

“We found that the regulator GATA3 is doing two jobs at once. It helps drive an inflammatory signal in GVHD, but it also prevents those same immune cells from becoming even more aggressive. When we removed it, the disease actually got worse,” said Mark Castleberry, PhD, Research Scientist.

In preclinical models of GVHD, the team showed that GATA3 is part of a larger regulatory system inside immune cells. While it contributes to inflammation, it also keeps those cells from shifting into a more damaging inflammatory program. The findings suggest that targeting inflammation after transplant requires a deeper understanding of how immune cells are transcriptionally programmed not just what cytokines they produce.

Dr. Castleberry, first author of the study, recently presented this work at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, the world’s leading conference in hematology. Out of more than 8,000 abstracts submitted, the study was selected as one of only 17 highlighted among the best of the meeting, placing the work from the Drobyski Lab and the MCW Cancer Center among the most impactful transplant research presented globally.

One Molecule, Two Roles

When GVHD affects the gut, inflammation can become overwhelming. Immune cells enter the colon and release signals that damage the tissue. Among the most important of these signals is a molecule called GM-CSF, which acts like an amplifier for inflammation.

For years, scientists have believed that reducing GM-CSF would reduce GVHD severity. The team wanted to test that idea more carefully by asking a deeper question: what controls GM-CSF production inside these immune cells? Using genetic tools and disease models, they identified several regulators that act like internal control switches. When two of those switches were removed in mouse models, inflammation decreased and survival improved. That result aligned with expectations.

But when they removed GATA3, the results were unexpected. GM-CSF levels went down. However, the immune cells did not calm down. Instead, they shifted into a different, more aggressive inflammatory state and caused more damage. “It really shows how layered and context-specific the immune system is,” said Dr. Castleberry.

The key insight is this: inflammation in GVHD is not driven by one molecule alone. It is shaped by broader genetic programming inside the cell. Removing one signal can cause the immune system to compensate in ways that are even more harmful.

“This changes how we think about targeting GVHD,” said Dr. Castleberry. “It’s not just about blocking one molecule. We have to understand how these cells are programmed in the environment they’re in, especially in the gut.”

That shift toward understanding the full program inside immune cells, and how the gut environment shapes that program, is helping refine how transplant-related complications are approached. Rather than broadly suppressing inflammation, the goal becomes more precise: protect the cancer-fighting immune response while preventing it from turning destructive.

Looking ahead, the team plans to dig even deeper. Rather than focusing only on what immune cells are doing in the gut, they want to understand what signals from the gut environment are instructing those cells to behave the way they do. By decoding those signals, the Drobyski Lab hopes to move transplant medicine closer to preventing GVHD rather than reacting to it.

Learn more about the study.